Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
tremelimumab actl 300 mg/15 mL Sol (OTHER 8275471-72026826) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 4, 2026 , from http://ppman.hank.ai/transparency/procedure/8275471-72026826/by-state?code_type=OTHER
“tremelimumab actl 300 mg/15 mL Sol (OTHER 8275471-72026826) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/8275471-72026826/by-state?code_type=OTHER. Accessed
July 4, 2026 .
“tremelimumab actl 300 mg/15 mL Sol (OTHER 8275471-72026826) by State,” HANK Price Transparency ,
accessed July 4, 2026 ,
http://ppman.hank.ai/transparency/procedure/8275471-72026826/by-state?code_type=OTHER.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
OTHER · across United States
8275471-72026826 — Tremelimumab Actl 300 Mg/15 Ml Sol
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$142,028
National median
$43,407 – $172,271
IQR (p25 – p75)
2
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for 8275471-72026826 (OTHER), with interquartile range
State Median p25 p75
GA $142,028 $43,407 $172,271